This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Price, L. B.
Right arrow Articles by Keim, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Price, L. B.
Right arrow Articles by Keim, P.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 2003, p. 2362-2365, Vol. 47, No. 7
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.7.2362-2365.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

In Vitro Selection and Characterization of Bacillus anthracis Mutants with High-Level Resistance to Ciprofloxacin

Lance B. Price,1,2 Amy Vogler,1 Talima Pearson,1 Joseph D. Busch,1 James M. Schupp,1 and Paul Keim1*

Department of Biological Sciences, Northern Arizona University, Flagstaff, Arizona 86011-5640,1 Environmental Health Sciences, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland 212052

Received 13 August 2002/ Returned for modification 28 October 2002/ Accepted 26 March 2003


arrow
ABSTRACT
 
Mutants of attenuated Bacillus anthracis with high-level ciprofloxacin resistance were isolated using a three-step in vitro selection. Ciprofloxacin MICs were 0.5 µg/ml for first-step mutants, which had one of two gyrA quinolone resistance-determining region (QRDR) mutations. Ciprofloxacin MICs were 8 and 16 µg/ml for second-step mutants, which had one of three parC QRDR mutations. Ciprofloxacin MICs for third-step mutants were 32 and 64 µg/ml. Mutants for which MICs were 64 µg/ml had one of two additional mutations within the gyrA QRDR or one of two mutations within the gyrB QRDR. Mutants for which MICs were 32 µg/ml had no additional target modifications but showed evidence of enhanced ciprofloxacin efflux.


arrow
TEXT
 
Bacillus anthracis is a spore-forming zoonotic pathogen that occasionally infects humans, causing cutaneous, intestinal, or pulmonary forms of anthrax (9, 11). Although all three human disease forms are rare, the potential for using B. anthracis as a biological weapon makes development of antimicrobial resistance a particularly relevant concern. The two recommended therapeutics for human anthrax are doxycycline (DOX) and ciprofloxacin (CIP) (3, 4, 11). Natural resistance to CIP and DOX is undocumented (4, 5, 6); however, resistance to each has been obtained in vitro (2, 22). DOX resistance was conferred on B. anthracis by transfection with the pBC16 plasmid carrying the tetracycline resistance gene, tet (22). CIP resistance was selected through serial passage, though the genotypic determinants eliciting resistance were not characterized (2).

The bactericidal action of CIP results from the binding of gyrase-DNA and topoisomerase IV-DNA complexes and the release of DNA with double-stranded breaks (for review, see references 7 and 21). Most fluoroquinolone-resistant mutants have amino acid changes in quinolone resistance-determining regions (QRDRs) of the GyrA subunit of gyrase and the ParC subunit of topoisomerase IV. However, resistance can also arise from the overexpression of multidrug transporters and residue changes in the QRDRs of the GyrB and ParE subunits of gyrase and topoisomerase IV. Low-level resistance can be acquired with a single missense mutation within a QRDR or a point mutation in the regulatory region of an efflux pump, but high-level resistance requires a combination of mutations. The stepwise accumulation of QRDR mutations required for high-level CIP resistance follows a species-specific pathway in vitro (8, 19). However, the utility of these in vitro studies for predicting the progression of a given species to a high-level fluoroquinolone-resistant phenotype in vivo is not clear (12, 25).

In order to characterize CIP resistance determinants and mutation rates in B. anthracis, we used an in vitro stepwise selection procedure (8) to develop high-level CIP-resistant mutants. Mutation rates were determined using a Luria-Delbruck model (15), and genotypes of resistant strains were determined at each step. CIP MICs were determined for each unique mutant. Finally, multidrug efflux inhibitors were used to test for enhanced CIP efflux.

Stepwise selection and isolation of high-level CIP-resistant mutants. Spontaneous CIP-resistant mutants of the attenuated B. anthracis {Delta}ANR strain (plasmid-cured Ames strain) were selected in a three-step process using standard microbiological techniques. Colonies from blood agar plates were used to inoculate culture tubes containing 5 ml of Mueller-Hinton (MH) broth (Difco). Cultures were incubated overnight at 37°C and then transferred to 0.45-µm-pore-size nitrocellulose membrane filters (Millipore). Membranes were placed cell side up onto MH agar containing CIP at three to four times the MIC for the parent strain (8) and incubated for ~40 h. A single colony from each positive plate was cataloged (either as a frozen stock or as a spore stock) and analyzed for topoisomerase mutations in the gyrA and parC QRDRs by fluorescent DNA sequence analysis (gyrB and parE QRDRs were analyzed at the end of the study). QRDRs were amplified by PCR using primers designed from the incomplete B. anthracis genome sequence (Table 1; The Institute for Genomic Research, Rockville, Md.). Fifty-microliter PCRs were prepared in PCR buffer (20 mM Tris [pH 8.4], 50 mM KCl) (Gibco) using 0.10 mM deoxynucleoside triphosphates, 2 mM MgCl2, ~5 ng of template DNA prepared as described previously (14), 0.04 U of Taq DNA polymerase/µl (Gibco), and 0.2 µM forward and reverse primers. Reactions were heated to 94°C for 5 min and then cycled 35 times at 94, 60, and 72°C for 20 s at each temperature. PCR products were sequenced on either an ABI377 or an ABI3100 fluorescent sequencer using the ABI PRISM Ready Reaction BigDye terminator cycle sequencing kit according to the manufacturer’s specifications (Applied Biosystems). The most common unique genotype from each selection step was used for subsequent selections until high-level CIP-resistant strains were identified.


View this table:
[in this window]
[in a new window]
  		TABLE 1. Primers used in this study

Susceptibility testing. MICs were determined by the agar dilution method. Cultures were grown overnight on MH agar supplemented with 5% sheep blood. Colonies were suspended in MH broth to a density equivalent of a 0.5 McFarland standard. Two microliters of this suspension was dropped onto agar dilution plates. Once the spots had been absorbed, the plates were inverted and incubated for 24 h at 35°C. B. anthracis {Delta}ANR was used as the reference strain for determinations of MICs for mutants.

Mutation rate estimation. Mutation rates for first-, second-, and third-step CIP-resistant mutants were estimated with 96 independent cultures of B. anthracis {Delta}ANR, S1-1, and S2-1, respectively (Table 2). A single colony of the starting isolate was suspended in Luria-Bertani (LB) broth and used to inoculate each of the independent cultures with approximately 1,000 cells. For first- and third-step mutants, 96 1-ml cultures were grown in LB broth in four 24-well plates (Costar). For step 2, 96 100-µl cultures were grown in LB broth in a single 96-well plate (Costar). All plates were incubated overnight at 37°C in a G24 environmental incubator shaker (New Brunswick Scientific) with shaking at 225 rpm. Six cultures were chosen at random for each step and used to determine the average total number of cells present in each culture. The remaining 90 cultures were plated onto MH plates with CIP concentrations of 0.25, 1.5, and 24 µg/ml for steps 1, 2, and 3, respectively. For step 2, the 100-µl cultures were plated directly. For steps 1 and 3, the 1-ml cultures were transferred to sterile 1.5-ml microcentrifuge tubes and centrifuged at 3,000 x g for 5 min. Approximately 850 µl of the supernatant was removed, and the pellet was resuspended in the remaining broth and plated. All of the plates were incubated at 37°C for ~48 h. Up to four putative resistant colonies from each positive plate were transferred to fresh selective medium and incubated at 37°C for ~48 h to confirm resistance. The number of plates devoid of resistant mutants represents zero mutational events. This value was used with the cell count in the Poisson distribution to estimate the mutation rate for each step (15).


View this table:
[in this window]
[in a new window]
  		TABLE 2. Mutants identified in this study

Mutations and mutation rates. The sequential selection of B. anthracis on increasing CIP concentrations resulted in a stepwise accumulation of mutations, leading to mutants for which CIP MICs were as high as 64 µg/ml (~1,000-fold higher than that for the wild type) (Table 2). First-step mutants developed at a rate of 6.6 x 10-10 and had one of two mutations within the gyrA QRDR (Table 2). Eighty percent of these mutants possessed a C254->T missense mutation in gyrA (Table 2). (Note that other, rarer gyrA mutations were identified; however, these strains died during the cataloging process due to an asporogenic state and remain unconfirmed.) Second-step mutants developed at a rate of 1.0 x 10-8 and possessed one of three mutations within the parC QRDR (Table 2). As with the S1 mutants, one transition, C242->T, was overrepresented (73%) (Table 2). Third-step mutants developed at a rate of 4.8 x 10-10. In total, fourteen S3 mutants were isolated, nine for which CIP MICs were 32 µg/ml and five for which MICs were 64 µg/ml. Mutants for which MICs were 64 µg/ml had one of two additional mutations within the gyrA QRDR or one of two mutations within the gyrB QRDR (Table 2). Mutants for which MICs were 32 µg/ml were devoid of additional mutations within any of the topoisomerase QRDRs, gyrA, gyrB, parC and parE.

Evidence of multidrug efflux. The absence of additional missense mutations in the QRDRs of many (65%) third-step mutants led to investigations into multidrug transport. Blast searches of the partial B. anthracis genome sequence with the gene sequences of the B. subtilis multidrug efflux pumps bmr (gb L25604) and blt (gb L32599) (1) revealed homologues of each. Both of these pumps are members of the major facilitator superfamily and can externalize a diverse group of chemicals, including fluoroquinolones, ethidium bromide, rhodamine dyes, and chloramphenicol (1, 17, 18). Interestingly, ethidium bromide MICs were not increased for any of the CIP-resistant mutants. However, susceptibility to CIP in the presence of the potent efflux inhibitor INF271 (20 µg/ml) was increased eightfold in the nine S3 mutants devoid of additional QRDR mutations (Fig. 1) (16). The susceptibility of the S2 parent strain and the other five S3 mutants was increased only twofold (a one- to twofold increase in CIP susceptibility was observed for all S1 and S2 strains [data not shown]). Disruption of the high-level resistant phenotype among the nine putative efflux mutants was confirmed with another structurally unrelated multidrug transport inhibitor, reserpine (Sigma) (16; data not shown).



View larger version (21K):
[in this window]
[in a new window]
  		FIG. 1. Effect of INF271 on the susceptibility of third-step, high-level CIP-resistant B. anthracis mutants. S2-1 is the parent strain for the third-step mutants; S3-1, -3, -4, -5, -7, -12, -14, -15, and -17 are third-step mutants with no additional gyrase or topoisomerase mutations. S3-6, -8, -11, and -16 are third-step mutants with additional gyrase mutations. {Delta}{Delta}, Bacillus subtilis with inactivated blt and bmr transporter genes; {Delta}{Delta}NA, B. subtilis strain {Delta}{Delta} with a functional NorA transporter from the plasmid expression vector pBEV.

The spontaneous stepwise resistance rates calculated in this study (6.6 x 10-10, 1.0 x 10-8, and 4.8 x 10-10) are similar to the rate calculated for rifampin resistance in B. anthracis (1.6 x 10-9) (24) and to those reported for fluoroquinolone resistance in other species (20, 23). These data confirm a normal mutation rate in B. anthracis and argue against a reduced mutation rate as a potential explanation for the lack of genetic diversity among B. anthracis isolates (10, 13, 14). The targeted stepwise accumulation of mutations (S1 gyrA -> S2 parC) in B. anthracis indicates that the primary target of CIP is GyrA and that the secondary target is ParC.

This is the first reported evidence of efflux-based CIP resistance in B. anthracis. Further characterization of this phenomenon will provide deeper insight into the different fluoroquinolone resistance mechanisms in this important pathogen.


arrow
ACKNOWLEDGMENTS
 
This project was funded by the Northern Arizona University Cowden Endowment for Microbiology.

We thank the following individuals for their contributions to this project: Timothy Read at The Institute for Genomic Research, for providing the unfinished B. anthracis genome sequence; Alexander Neyfakh at the University of Chicago, Center for Pharmaceutical Biotechnology, for kindly providing control strains and advice for the drug efflux experiments; Penelope Markham and Influx, Inc., Chicago, Ill., for generously providing INF271; Christine Tipton-Hunton for literature searches; and Michelle L. Cardon for DNA sequence analysis.


arrow
FOOTNOTES
 
* Corresponding author. Mailing address: Department of Biological Sciences, Northern Arizona University, Flagstaff, AZ 86011-5640. Phone: (928) 523-1078. Fax: (928) 523-0639. E-mail: Paul.Keim{at}nau.edu. Back


arrow
REFERENCES
 
    1
  1. Ahmed, M., L. Lyass, P. N. Markham, S. S. Taylor, N. Vazquez-Laslop, and A. A. Neyfakh. 1995. Two highly similar multidrug transporters of Bacillus subtilis whose expression is differentially regulated. J. Bacteriol. 177:3904-3910.[Abstract/Free Full Text]
    2. 2
  2. Brook, I., T. B. Elliott, H. I. Pryor II, T. E. Sautter, B. T. Gnade, J. H. Thakar, and G. B. Knudson. 2001. In vitro resistance of Bacillus anthracis Sterne to doxycycline, macrolides and quinolones. Int. J. Antimicrob. Agents 18:559-562.[CrossRef][Medline]
    3. 3
  3. Brook, I. 2002. The prophylaxis and treatment of anthrax. Int. J. Antimicrob. Agents 20:320-325.[CrossRef][Medline]
    4. 4
  4. Bryskier, A. 2002. Bacillus anthracis and antimicrobial agents. Clin. Microbial. Infect. 8:467-478.[CrossRef][Medline]
    5. 5
  5. Cavallo, J. D., F. Ramisse, M. Girardet, J. Vaissaire, M. Mock, and E. Hernandez. 2002. Antibiotic susceptibilities of 96 isolates of Bacillus anthracis isolated in France between 1994 and 2000. Antimicrob. Agents Chemother. 46:2307-2309.[Abstract/Free Full Text]
    6. 6
  6. Coker, P. R., K. L. Smith, and M. E. Hugh-Jones. 2002. Antimicrobial susceptibilities of diverse Bacillus anthracis isolates. Antimicrob. Agents Chemother. 46:3843-3845.[Abstract/Free Full Text]
    7. 7
  7. Drlica, K., and X. Zhao. 1997. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol. Mol. Biol. Rev. 61:377-392.[Abstract]
    8. 8
  8. Ferrero, L., B. Cameron, and J. Crouzet. 1995. Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus. Antimicrob. Agents Chemother. 39:1554-1558.[Abstract]
    9. 9
  9. Friedlander, A. M. 1999. Clinical aspects, diagnosis and treatment of anthrax. J. Appl. Microbiol. 87:303.[CrossRef][Medline]
    10. 10
  10. Harrell, L. J., G. L. Andersen, and K. H. Wilson. 1995. Genetic variability of Bacillus anthracis and related species. J. Clin. Microbiol. 33:1847-1850.[Abstract]
    11. 11
  11. Inglesby, T. V., T. O'Toole, D. A. Henderson, J. G. Bartlett, M. S. Ascher, E. Eitzen, A. M. Friedlander, J. Gerberding, J. Hauer, J. Hughes, J. McDade, M. T. Osterholm, G. Parker, T. M. Perl, P. K. Russell, K. Tonat; Working Group on Civilian Biodefense. 2002. Anthrax as a biological weapon, 2002. JAMA 288:2236-2252.
    12. 12
  12. Jones, M. E., D. F. Sahm, N. Martin, S. Scheuring, P. Heisig, C. Thornsberry, K. Kohrer, and F. Schmitz. 2000. Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from worldwide surveillance studies during the 1997-1998 respiratory season. Antimicrob. Agents Chemother. 44:462-466.[Abstract/Free Full Text]
    13. 13
  13. Keim, P., A. Kalif, J. Schupp, K. Hill, S. E. Travis, K. Richmond, D. M. Adair, M. Hugh-Jones, C. R. Kuske, and P. Jackson. 1997. Molecular evolution and diversity in Bacillus anthracis as detected by amplified fragment length polymorphism markers. J. Bacteriol. 179:818-824.[Abstract/Free Full Text]
    14. 14
  14. Keim, P., L. B. Price, A. M. Klevytska, K. L. Smith, J. M. Schupp, R. Okinaka, P. J. Jackson, and M. E. Hugh-Jones. 2000. Multiple-locus variable-number tandem repeat analysis reveals genetic relationships within Bacillus anthracis. J. Bacteriol. 182:2928-2936.[Abstract/Free Full Text]
    15. 15
  15. Luria, S. E., and M. Delbruck. 1943. Mutations of bacteria from virus sensitivity to virus resistance. Genetics 28:491-511.[Free Full Text]
    16. 16
  16. Markham, P., N. E. Westhaus K. Klyachko, M. E. Johnson, and A. A. Neyfakh. 1999. Multiple novel inhibitors of the NorA multidrug transporter of Staphylococcus aureus. 43:2404-2408.
    17. 17
  17. Neyfakh, A. A. 1992. The multidrug efflux transporter of Bacillus subtilis is a structural and functional homolog of the Staphylococcus NorA protein. Antimicrob. Agents Chemother. 36:484-485.[Abstract/Free Full Text]
    18. 18
  18. Neyfakh, A. A., C. M. Borsch, and G. W. Kaatz. 1993. Fluoroquinolone resistance protein NorA of Staphylococcus aureus is a multidrug efflux transporter. Antimicrob. Agents Chemother. 37:128-129.[Abstract/Free Full Text]
    19. 19
  19. Ng, E. Y., M. Trucksis, and D. C. Hooper. 1996. Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus. Antimicrob. Agents Chemother. 40:1881-1888.[Abstract]
    20. 20
  20. Pan, X. S., and L. M. Fisher. 1998. DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 42:2810-2816.[Abstract/Free Full Text]
    21. 21
  21. Piddock, L. J. 1999. Mechanisms of fluoroquinolone resistance: an update, 1994-1998. Drugs. 58:11-18.
    22. 22
  22. Pomerantsev, A. P., N. A. Shishkova, and L. I. Marinin. 1992. Comparison of therapeutic effects of antibiotics of the tetracycline group in the treatment of anthrax caused by a strain inheriting tet-gene of plasmid pBC16. Antibiot. Khimioter. 37:31-34.
    23. 23
  23. Schedletzky, H., B. Wiedemann, and P. Heisig. 1999. The effect of moxifloxacin on its target topoisomerases from Escherichia coli and Staphylococcus aureus. J. Antimicrob. Chemother. 43:31-37.[Abstract]
    24. 24
  24. Vogler, A. J., J. D. Busch, S. Percy-Fine, C. M. Tipton-Hunton, K. L. Smith, and P. Keim. 2001. Molecular analysis of rifampicin resistance in Bacillus anthracis and Bacillus cereus. J. Antimicrob. Chemother. 46:511-513.
    25. 25
  25. Weigel, L. M., G. J. Anderson, R. R. Facklam, and F. C. Tenover. 2001. Genetic analysis of mutations contributing to fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45:3517-3523.[Abstract/Free Full Text]

Antimicrobial Agents and Chemotherapy, July 2003, p. 2362-2365, Vol. 47, No. 7
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.7.2362-2365.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Heine, H. S., Bassett, J., Miller, L., Bassett, A., Ivins, B. E., Lehoux, D., Arhin, F. F., Parr, T. R. Jr., Moeck, G. (2008). Efficacy of Oritavancin in a Murine Model of Bacillus anthracis Spore Inhalation Anthrax. Antimicrob. Agents Chemother. 52: 3350-3357 [Abstract] [Full Text]  
  • Heine, H. S., Bassett, J., Miller, L., Hartings, J. M., Ivins, B. E., Pitt, M. L., Fritz, D., Norris, S. L., Byrne, W. R. (2007). Determination of Antibiotic Efficacy against Bacillus anthracis in a Mouse Aerosol Challenge Model. Antimicrob. Agents Chemother. 51: 1373-1379 [Abstract] [Full Text]  
  • Brook, I., Germana, A., Giraldo, D. E., Camp-Hyde, T. D., Bolduc, D. L., Foriska, M. A., Elliott, T. B., Thakar, J. H., Shoemaker, M. O., Jackson, W. E., Ledney, G. D. (2005). Clindamycin and quinolone therapy for Bacillus anthracis Sterne infection in 60Co-gamma-photon-irradiated and sham-irradiated mice. J Antimicrob Chemother 56: 1074-1080 [Abstract] [Full Text]  
  • Poole, K. (2005). Efflux-mediated antimicrobial resistance. J Antimicrob Chemother 56: 20-51 [Abstract] [Full Text]  
  • Korzheva, N., Davies, T. A., Goldschmidt, R. (2005). Novel Ser79Leu and Ser81Ile Substitutions in the Quinolone Resistance-Determining Regions of ParC Topoisomerase IV and GyrA DNA Gyrase Subunits from Recent Fluoroquinolone-Resistant Streptococcus pneumoniae Clinical Isolates. Antimicrob. Agents Chemother. 49: 2479-2486 [Abstract] [Full Text]  
  • Grohs, P., Podglajen, I., Gutmann, L. (2004). Activities of Different Fluoroquinolones against Bacillus anthracis Mutants Selected In Vitro and Harboring Topoisomerase Mutations. Antimicrob. Agents Chemother. 48: 3024-3027 [Abstract] [Full Text]  
  • Athamna, A., Athamna, M., Abu-Rashed, N., Medlej, B., Bast, D. J., Rubinstein, E. (2004). Selection of Bacillus anthracis isolates resistant to antibiotics. J Antimicrob Chemother 54: 424-428 [Abstract] [Full Text]  
  • Bast, D. J., Athamna, A., Duncan, C. L., de Azavedo, J. C. S., Low, D. E., Rahav, G., Farrell, D., Rubinstein, E. (2004). Type II topoisomerase mutations in Bacillus anthracis associated with high-level fluoroquinolone resistance. J Antimicrob Chemother 54: 90-94 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Price, L. B.
Right arrow Articles by Keim, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Price, L. B.
Right arrow Articles by Keim, P.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»